Cochrane · systematic review · CD012540
Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease
Boyapati, RK, Torres, J, Palmela, C, et al. · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
GutAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
8
current version
GRADE rated
8
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 4 · 50%Low 4 · 50%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Usual care compared to immunosuppressive withdrawal after monotherapy for patients with quiescent Crohn's disease
Population: Patients with quiescent Crohn's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Relapse at 12, 18 or 24 months Usual care vs immunosuppressive withdrawal after monotherapy | RR 0.42 [0.24, 0.72] | 4 studies · 215 participants | Low Downgraded: risk of bias, imprecision |
New CD‐related complications Usual care vs immunosuppressive withdrawal after monotherapy | RR 0.34 [0.06, 2.08] | 2 studies · 135 participants | Very low Downgraded: risk of bias, imprecision |
Adverse events Usual care vs immunosuppressive withdrawal after monotherapy | RR 0.88 [0.67, 1.17] | 3 studies · 186 participants | Low Downgraded: risk of bias, imprecision |
Serious adverse events Usual care vs immunosuppressive withdrawal after monotherapy | RR 3.29 [0.35, 30.8] | 2 studies · 134 participants | Very low Downgraded: risk of bias, imprecision |
Withdrawal due to adverse events Usual care vs immunosuppressive withdrawal after monotherapy | RR 2.59 [0.35, 19.04] | 2 studies · 135 participants | Very low Downgraded: risk of bias, imprecision |
Usual care compared to immunosuppressive withdrawal after combination therapy for patients with quiescent Crohn's disease
Population: Patients with quiescent Crohn's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Relapse at 12 or 24 months Usual care vs immunosuppressive withdrawal after combination therapy | RR 1.02 [0.68, 1.52] | 2 studies · 111 participants | Low Downgraded: risk of bias |
Adverse events Usual care vs immunosuppressive withdrawal after combination therapy | RR 1.11 [0.44, 2.81] | 2 studies · 111 participants | Low Downgraded: risk of bias |
Serious adverse events Usual care vs immunosuppressive withdrawal after combination therapy | RR 1 [0.21, 4.66] | 1 study · 80 participants | Very low Downgraded: risk of bias |